Compare Wahed FTSE USA Shariah ETF (HLAL) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs McKesson Corporation — how do they compare? Wahed FTSE USA Shariah ETF trades at $70.99, while McKesson Corporation trades at $829.95 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| HLAL | MCK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $995.69 |
52-Week Low | $54.05 | $659.01 |
Market Cap | — | $97.35B |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, reflecting modest near-term pressure. Key financial ratios such as P/E, P/S, and ROE are not available in the current dataset, limiting fundamental visibility. A dividend of $0.02 is scheduled for June 2026, indicating a long-term income component. Trading volume and technical levels require additional market data for full context.
The outlook for HLAL hinges on upcoming financial disclosures to assess valuation and profitability. Investment opportunity lies in potential earnings growth and dividend yield, but risks include lack of current fundamental data and market volatility. Investors should await SEC filings for a clearer picture of the company's financial health.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
